Modern science offers a novel strategy to target the most challenging infections fueled by biofilms. Learn more about our important work to combat these infections and reduce antibiotic resistance.Our Science An innovative, strategically focused management team with deep anti-infective therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory BoardsMay 28, 2024 Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline MomentumApril 22, 2024 Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial InfectionsJanuary 5, 2024 Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody TherapyJune 1, 2023